the Synergistic Compatibility Framework
  • Home
  • What's Inside the Framework
  • SCF Developments
  • SCF Publications
  • SCF Systems Therapeutic’s AI Ecosystem

PRISM™ Platform: Precision Immune Restoration — Sequenced by Biology, Not by Dose

At SCF Biotech, we do not stimulate the immune system blindly.

We restore immune identity through biologically gated sequencing.

PRISM™ (Platform for Regulated Immune Structural Modulation) is a mechanistic, biomarker-driven therapeutic architecture designed to repair immune collapse across post-viral disease, oncology-associated lymphopenia, and aging-related immune decline.

Unlike conventional immune therapies that escalate dose when results falter, PRISM enforces tiered biological readiness — ensuring that restorative signals are delivered only when the system is structurally and metabolically prepared to receive them  .

The Core Principle

Immune restoration is hierarchical.
Escalation is earned biologically — not scheduled temporally  .

Immune identity cannot regenerate in an unstable environment.

PRISM corrects the environment first.

The PRISM™ Five-Tier Architecture

PRISM is built on a universal immune collapse axis that applies across indications  .

Tier
Biological Domain
What Must Be Stabilized
Tier I
Metabolic & Redox Stability
Energy availability, mitochondrial competence
Tier II
Inflammatory Signal Control
Cytokine noise and innate overactivation
Tier III
Structural / Stromal Niche Readiness
Bone marrow & lymphoid ECM integrity
Tier IV
Epigenomic & Lineage Readiness
Receptor fidelity and gene accessibility
Tier V
Lineage Restoration
Durable immune identity regeneration

Each tier has:

  • Entry criteria
  • Exit criteria
  • Escalation rules
  • Rollback conditions

No tier may be skipped.

Why Sequencing Matters

Immune restoration fails when signals arrive before the system is ready to decode them.

PRISM enforces stepwise correction because:

  • Structural damage cannot be corrected by cytokines
  • Inflammatory noise corrupts regenerative signals
  • Epigenomic exhaustion blocks lineage renewal

For example, IL-7–mediated lineage restoration is powerful but high-risk. It may only proceed after structural and inflammatory permissivity are confirmed  .

This is not combination dosing.

This is conditional therapeutic sequencing.

Biomarker-Gated Escalation

PRISM does not escalate by calendar or protocol habit.

Progression between tiers requires:

  • Structural normalization
  • Stable inflammatory profile
  • No aberrant proliferation signals
  • Disease-specific control maintained

If instability appears, the system rolls back to the lowest unstable tier — never dose escalation  .

This design enhances:

  • Safety
  • Regulatory interpretability
  • Signal durability

Cross-Disease Platform Strategy

PRISM scales across immune collapse indications while respecting biological boundaries  .

Oncology-Associated Lymphopenia

  • High translational clarity
  • Structural repair → lineage restoration
  • Strongest non-infectious expansion pathway

Post-Viral Immune Collapse

  • Strict biomarker gating
  • Restoration only after viral clearance and inflammatory containment

Aging-Associated Immunosenescence

  • Investigational, tightly controlled exploration

PRISM prevents indication-driven misuse by enforcing tier-based biological truth  .

What Makes PRISM Different

Conventional Approach
PRISM™ Platform
Dose escalation for non-response
Rollback to unstable tier
Concurrent combination therapy
Conditional, stepwise sequencing
Inflammation tolerated during restoration
Inflammation must be neutralized first
Structure ignored
Structural priming required
Fixed protocol timing
Biomarker-gated progression

PRISM integrates:

  • Mechanistic logic
  • Structural biology
  • Epigenomic permissivity
  • Safety-first cytokine deployment

All structured for IND, DSMB, and FDA interpretability  .

Our Strategic Vision

We are building a platform where:

  • Immune restoration is predictable
  • Cytokine therapies are constrained and controlled
  • Structural repair precedes activation
  • Safety is engineered into sequencing logic

PRISM is not a single drug.

It is a regulatory-ready immune restoration system.

SCF Biotech

Sequenced. Gated. Restorative.

We do not push the immune system forward.

We prepare it — and then restore it — when biology says it is ready.

the Synergistic Compatibility Framework

About the Company

Contact

Regulatory Disclaimer

Terms of Use